Professional
Added to YB: 2025-10-29
Pitch date: 2025-09-30
SUPN [neutral]
Supernus Pharmaceuticals, Inc.
-0.97%
current return
Author Info
No bio for this author
Company Info
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.
Market Cap
$2.6B
Pitch Price
$47.62
Price Target
N/A
Dividend
N/A
EV/EBITDA
17.54
P/E
-131.74
EV/Sales
3.44
Sector
Pharmaceuticals
Category
growth
Third Avenue Small-Cap Value Fund Portfolio Holding: Supernus Pharmaceuticals, Inc.
SUPN (holding update): Benefiting from strong financial position, current profitability, expanding neurology drug portfolio, and strong capital allocation framework that led to attractive acquisition completed during quarter. Largest positive contributor to fund performance.
Read full article (1 min)